Takashi Seto

List of Publications by Year
in descending order

55	14,111	147566	168136
papers	citations	31 h-index	53 g-index

55	55	55	11663
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study). , 2022, 10, e004025.		22
2	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors. Clinical Cancer Research, 2022, 28, 1302-1312.	3.2	74
3	Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial. Journal of Thoracic Oncology, 2021, 16, 452-463.	0.5	51
4	Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies. JTO Clinical and Research Reports, 2021, 2, 100108.	0.6	20
5	NTRK Fusion-positive Nonâ€“small-cell Lung Cancer: The Diagnosis and Targeted Therapy. Clinical Lung Cancer, 2021, 22, 1-5.	1.1	43
6	Capmatinib in Japanese patients with MET exon 14 skippingâ€“mutated or MET â€amplified advanced NSCLC: GEOMETRY monoâ€1 study. Cancer Science, 2021, 112, 1556-1566.	1.7	12
7	Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring <scp>MET</scp> exon 14 skipping mutation. Thoracic Cancer, 2021, 12, 978-980.	0.8	12
8	Sarcoidâ€like reaction of the extrathoracic lymph node in a patient with lung adenocarcinoma treated with pembrolizumab. Thoracic Cancer, 2021, 12, 2122-2125.	0.8	6
9	The mechanisms of resistance to second- and third-generation ALK inhibitors and strategies to overcome such resistance. Expert Review of Anticancer Therapy, 2021, 21, 975-988.	1.1	10
10	Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset. JTO Clinical and Research Reports, 2021, 2, 100171.	0.6	5
11	The 2020 Edition of the Clinical Guidelines for Lung Cancer: Challenges and Future Perspectives. Japanese Journal of Lung Cancer, 2021, 61, 163-170.	0.0	0
12	RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2021, 27, 5258-5271.	3.2	23
13	Treatment Patterns in Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: Analysis of US Insurance Claims Databases. Drugs - Real World Outcomes, 2021, , 1.	0.7	3
14	Phase 1 study of pembrolizumab plus chemotherapy as first-line treatment in Japanese patients with advanced NSCLC. Cancer Treatment and Research Communications, 2021, 29, 100458.	0.7	4
15	Successful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapy. Thoracic Cancer, 2021, 12, 3286-3289.	0.8	1
16	Therapies after first-line afatinib in patients with EGFRm⁺ NSCLC in Japan: retrospective analysis of LUX-Lung 3. Future Oncology, 2020, 16, 49-60.	1.1	4
17	Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1â€“2 trials. Lancet Oncology, The, 2020, 21, 261-270.	5.1	303
18	Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1â€“2 trials. Lancet Oncology, The, 2020, 21, 271-282.	5.1	1,034

#	Article	IF	Citations
19	Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. Lung Cancer, 2020, 139, 195-199.	0.9	100
20	Lorlatinib in previously treated anaplastic lymphoma kinaseâ€rearranged nonâ€“small cell lung cancer: Japanese subgroup analysis of a global study. Cancer Science, 2020, 111, 3726-3738.	1.7	12
21	Cohesion between pulmonary artery and bronchus after immune checkpoint inhibitor therapy in a lung cancer patient. Thoracic Cancer, 2020, 11, 3605-3608.	0.8	6
22	Erlotinib for Nonâ€Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101) Tj ETQq0 0 0 rgBT /Overlock	1.9	10
23	Capmatinib inMETExon 14â€“Mutated orMET-Amplified Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2020, 383, 944-957.	13.9	542
24	Brain cavernous hemangioma mimicking radiationâ€induced necrosis in a patient with nonâ€small cell lung cancer. Thoracic Cancer, 2020, 11, 2056-2058.	0.8	1
25	Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer. Lung Cancer, 2020, 144, 10-19.	0.9	14
26	U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2020, 26, 4785-4794.	3.2	63
27	Short progressionâ€free survival of ALK inhibitors sensitive to secondary mutations in ALKâ€positive NSCLC patients. Thoracic Cancer, 2019, 10, 1779-1787.	0.8	7
28	Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 1655-1669.	5.1	418
29	The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. International Journal of Clinical Oncology, 2019, 24, 731-770.	1.0	100
30	<scp>KEYNOTE</scp>â€025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1â€“positive advanced nonâ€“smallâ€cell lung cancer. Cancer Science, 2019, 110, 1012-1020.	1.7	40
31	Phase I doseâ€escalation study of capmatinib (<scp>INC</scp>280) in Japanese patients with advanced solid tumors. Cancer Science, 2019, 110, 1340-1351.	1.7	33
32	Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncology, The, 2018, 19, 1654-1667.	5.1	587
33	Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date. OncoTargets and Therapy, 2018, Volume 11, 5093-5101.	1.0	43
34	Clinical activity of <scp>ASP</scp>8273 in Asian patients with nonâ€smallâ€cell lung cancer with <scp>EGFR</scp> activating and T790M mutations. Cancer Science, 2018, 109, 2852-2862.	1.7	15
35	Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutationâ€“positive non-squamous nonâ€“small-cell lung cancer (NSCLC): Survival follow-up results of JO25567.. Journal of Clinical Oncology, 2018, 36, 9007-9007.	0.8	53
36	Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study. Oncotarget, 2018, 9, 23729-23737.	0.8	33

#	Article	IF	Citations
37	Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet, The, 2017, 390, 29-39.	6.3	753
38	Wâ€˜ALKâ€™ Into the Next Stage. Clinical Lung Cancer, 2017, 18, 122-126.	1.1	6
39	Updated efficacy and safety of the j-alex study comparing alectinib (ALC) with crizotinib (CRZ) in ALK-inhibitor naÃ¯ve ALK fusion positive non-small cell lung cancer (ALK+ NSCLC).. Journal of Clinical Oncology, 2017, 35, 9064-9064.	0.8	14
40	Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients. Japanese Journal of Clinical Oncology, 2016, 46, 462-467.	0.6	54
41	Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, 9022-9022.	0.8	14
42	Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Nonâ€“small-cell Lung Cancer Exhibiting Resistance to Ceritinib. Journal of Thoracic Oncology, 2015, 10, e55-e57.	0.5	60
43	Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Nonâ€“Small-Cell Lung Cancer or Other Tumors. Journal of Thoracic Oncology, 2015, 10, 1058-1066.	0.5	66
44	Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical Data. Oncology Research and Treatment, 2015, 38, 291-298.	0.8	82
45	Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2015, 16, 1630-1638.	5.1	75
46	Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib. Journal of Thoracic Oncology, 2014, 9, e86-e87.	0.5	69
47	Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncology, The, 2014, 15, 1236-1244.	5.1	678
48	A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC). Lung Cancer, 2013, 82, 109-114.	0.9	84
49	CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1â€“2 study. Lancet Oncology, The, 2013, 14, 590-598.	5.1	555
50	Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung Cancer. New England Journal of Medicine, 2013, 368, 2385-2394.	13.9	3,181
51	Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR).. Journal of Clinical Oncology, 2012, 30, 7521-7521.	0.8	71
52	Phase III Trial Comparing Oral S-1 Plus Carboplatin With Paclitaxel Plus Carboplatin in Chemotherapy-NaÃ¯ve Patients With Advanced Nonâ€“Small-Cell Lung Cancer: Results of a West Japan Oncology Group Study. Journal of Clinical Oncology, 2010, 28, 5240-5246.	0.8	161
53	Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncology, The, 2010, 11, 121-128.	5.1	3,794
54	Predictive Factors for Interstitial Lung Disease, Antitumor Response, and Survival in Nonâ€“Small-Cell Lung Cancer Patients Treated With Gefitinib. Journal of Clinical Oncology, 2006, 24, 2549-2556.	0.8	348

#	Article	IF	Citations
55	Phase III Study of Docetaxel Compared With Vinorelbine in Elderly Patients With Advanced Nonâ€“Small-Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). Journal of Clinical Oncology, 2006, 24, 3657-3663.	0.8	342